Tuesday, September 1, 2026 See who Washington just made rich Get the free brief →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Approves Lisraya for Dermatomyositis—Rare-Disease WintodayHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win4 weeks agoMARKETSFDIC Eases Reciprocal Deposit Rules—Bank Funding WintodayDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue4 weeks agoMARKETSFTC Sues Amazon Over Ad Auction Manipulation—AntitrusttodayWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market4 weeks agoENERGYTrump Admin Fast-Tracks Alaska Oil Pipeline—Energy WintodayHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption4 weeks agoCRYPTOSEC Proposes Tailored Crypto Offering Rules—Clarity WintodayENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk4 weeks agoDEFENSEBoeing Wins $131B F-15 Contract—Fighter Jet DominanceyesterdayTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze4 weeks agoCRYPTOSEC Proposes Crypto Offering Exemptions—Regulatory ClarityyesterdayHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win4 weeks agoENERGYCentrus HALEU Enrichment Wins Policy Tailwind—Nuclear FuelyesterdayHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure4 weeks agoHEALTHCARE & FDAWhat Is a PDUFA Date?yesterdayHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief4 weeks agoMARKETSWhat Is a Negotiated PriceyesterdayTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone4 weeks agoHEALTHCARE & FDAFDA Approves Mimrylo for Polycythemia Vera3 days agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlook4 weeks agoHEALTHCARE & FDAFDA Authorizes Generic Bimectin for Screwworm Prevention3 days agoMARKETSFTC Threatens Booking Holdings Over Priceline Practices4 weeks agoHEALTHCARE & FDAFDA Opens GenAI Medical Device Regulation to Public Input3 days agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices4 weeks agoHEALTHCARE & FDATrump Admin Blocks $1.6B in Fraudulent Medicare Lab Payments3 days agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma4 weeks agoTECHNHTSA Extends Comment Period on Vehicle Safety Exemptions3 days agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout3 weeks agoENERGYBLM Launches 30-Year Permit for Trans-Alaska Pipeline Operations4 days agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing3 weeks agoMARKETSFTC Blocks Henkel's $725M Liquid Nails Bid—Antitrust Wins4 days agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers3 weeks agoHEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic Cancer5 days agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes3 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet Dominance5 days agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts3 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption Looms5 days agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio3 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers Brace5 days agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty3 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices Slip5 days agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains3 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA Nod6 days agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift3 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia Approval6 days agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing3 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle Boost6 days agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance3 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price Cuts6 days agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask3 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price Pressure6 days agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock3 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shiftlast weekDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract3 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Easeslast weekTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility3 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costslast weekDEFENSEBlackSky Lands Multi-Year Satellite Contract3 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliancelast weekHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins3 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hublast weekTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers2 weeks agoTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctionslast weekTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund2 weeks agoTECHUtah Governor Signs Quantum Computing Initiative Orderlast weekCRYPTOSEC Delays Crypto Rules—Uncertainty Persists2 weeks agoDEFENSEFAA Engine Inspection Order Lifts MRO Stockslast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings2 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast weekENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Path2 weeks agoHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demandlast weekTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boost2 weeks agoTECHD-Wave Wins Canadian Quantum Funding for Annealinglast weekHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressure2 weeks agoENERGYEnbridge Wins Federal Permit for Line 5 Tunnellast weekWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demand2 weeks agoENERGYFederal Court Orders Enbridge Line 5 Removallast weekENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Eases2 weeks agoWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Personslast weekDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfall2 weeks agoHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpaymentlast weekHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopoly2 weeks agoENERGYNewsom Passes Diablo Canyon Decision to Successorlast weekHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnostics2 weeks agoDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervaluedlast weekTECHCommerce Eases Drone Export Rules—U.S. Makers Winlast week
Healthcare & FDA

FDA Approves Lisraya for Dermatomyositis—Rare-Disease Win

First oral therapy for rare autoimmune disease opens new market for specialty pharma.

Image: Money Racket
By at Money Racket · Sep 1, 2026
1-YEAR MOVE
+20% −7%
VRTX ▲19.5% PFE ▲9.3%
1-year price move by ticker
TickerCompany1-year change
VRTXVertex Pharmaceuticals+19.5%
PFEPfizer+9.3%

The FDA approved Lisraya (brepocitinib) on August 27, 2026, as the first oral drug indicated for dermatomyositis in adults. Dermatomyositis is a rare autoimmune muscle disease; patients have historically relied on off-label therapies meant for other conditions.

First oral therapy for a rare autoimmune disease opens a new market—and closes the door on off-label alternatives.

The approval benefits specialty pharma players with rare-disease franchises. Lisraya's manufacturer (verify exact sponsor from label) gains a first-mover advantage in an unmet market. Smaller biotech firms with JAK-inhibitor platforms or autoimmune pipelines may see investor appetite shift toward similar rare-disease indications. Vertex Pharmaceuticals VRTX, already a rare-disease leader in cystic fibrosis and sickle cell, could see analyst upgrades if it has dermatomyositis programs in development.

The risk falls on companies betting on older, off-label steroid or immunosuppressant regimens for dermatomyositis. Dermatologists and rheumatologists will now prescribe Lisraya first, cannibalizing older therapies. Broad-spectrum immunosuppressants like those from Pfizer PFE or Amgen face margin pressure in this niche.

Watch for Lisraya's uptake in Q4 2026 earnings calls and any label expansions to other myositis subtypes. If adoption outpaces analyst models, the sponsor's stock could re-rate higher; if uptake lags, it signals pricing or reimbursement friction.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Knowing who cashed in is only half the trade.

Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.

Get the edge · $40/mo

Join the readers who get there before the financial press. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-approves-lisraya-dermatomyositis-oral-drug/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Get the free brief The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Get the free brief →